Clinical application of micronucleus test: A case-control study on the prediction of breast cancer risk/susceptibility

Claudia Bolognesi, Paolo Bruzzi, Viviana Gismondi, Samantha Volpi, Valeria Viassolo, Simona Pedemonte, Liliana Varesco

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The micronucleus test is a well-established DNA damage assay in human monitoring. The test was proposed as a promising marker of cancer risk/ susceptibility mainly on the basis of studies on breast cancer. Our recent metaanalysis showed that the association between micronuclei frequency, either at baseline or after irradiation, and breast cancer risk or susceptibility, has been evaluated in few studies of small size, with inconsistent results. The aim of the present study is to investigate the role of micronucleus assay in evaluating individual breast cancer susceptibility. Two-hundred and twenty untreated breast cancer patients and 295 female controls were enrolled in the study. All women were characterized for cancer family history and 155 subjects were evaluated for the presence of BRCA mutations. Micronuclei frequency was evaluated at baseline and after irradiation with 1-Gy gamma rays from a 137Cs source. The results show a non significant increase of frequency of micronucleated binucleated lymphocytes in cancer patients compared with the controls at baseline (Mean (S.E.): 16.8 (0.7) vs 15.7 (0.5), but not after irradiation (Mean (S.E.): 145.8 (3.0) vs 154.0 (2.6)). Neither a family history of breast cancer nor the presence of a pathogenic mutation in BRCA1/2 genes were associated with an increased micronuclei frequency. Our results do not support a significant role of micronucleus frequency as a biomarker of breast cancer risk/susceptibility.

Original languageEnglish
Article numbere112354
JournalPLoS One
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 21 2014

Fingerprint

Micronucleus Tests
case-control studies
breast neoplasms
Case-Control Studies
Irradiation
Breast Neoplasms
prediction
Assays
Lymphocytes
irradiation
testing
Biomarkers
Gamma rays
neoplasms
Genes
Association reactions
BRCA1 Gene
mutation
Neoplasms
Mutation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Clinical application of micronucleus test : A case-control study on the prediction of breast cancer risk/susceptibility. / Bolognesi, Claudia; Bruzzi, Paolo; Gismondi, Viviana; Volpi, Samantha; Viassolo, Valeria; Pedemonte, Simona; Varesco, Liliana.

In: PLoS One, Vol. 9, No. 11, e112354, 21.11.2014.

Research output: Contribution to journalArticle

@article{648c0edaa3bb4ac19820c9c328b6b278,
title = "Clinical application of micronucleus test: A case-control study on the prediction of breast cancer risk/susceptibility",
abstract = "The micronucleus test is a well-established DNA damage assay in human monitoring. The test was proposed as a promising marker of cancer risk/ susceptibility mainly on the basis of studies on breast cancer. Our recent metaanalysis showed that the association between micronuclei frequency, either at baseline or after irradiation, and breast cancer risk or susceptibility, has been evaluated in few studies of small size, with inconsistent results. The aim of the present study is to investigate the role of micronucleus assay in evaluating individual breast cancer susceptibility. Two-hundred and twenty untreated breast cancer patients and 295 female controls were enrolled in the study. All women were characterized for cancer family history and 155 subjects were evaluated for the presence of BRCA mutations. Micronuclei frequency was evaluated at baseline and after irradiation with 1-Gy gamma rays from a 137Cs source. The results show a non significant increase of frequency of micronucleated binucleated lymphocytes in cancer patients compared with the controls at baseline (Mean (S.E.): 16.8 (0.7) vs 15.7 (0.5), but not after irradiation (Mean (S.E.): 145.8 (3.0) vs 154.0 (2.6)). Neither a family history of breast cancer nor the presence of a pathogenic mutation in BRCA1/2 genes were associated with an increased micronuclei frequency. Our results do not support a significant role of micronucleus frequency as a biomarker of breast cancer risk/susceptibility.",
author = "Claudia Bolognesi and Paolo Bruzzi and Viviana Gismondi and Samantha Volpi and Valeria Viassolo and Simona Pedemonte and Liliana Varesco",
year = "2014",
month = "11",
day = "21",
doi = "10.1371/journal.pone.0112354",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Clinical application of micronucleus test

T2 - A case-control study on the prediction of breast cancer risk/susceptibility

AU - Bolognesi, Claudia

AU - Bruzzi, Paolo

AU - Gismondi, Viviana

AU - Volpi, Samantha

AU - Viassolo, Valeria

AU - Pedemonte, Simona

AU - Varesco, Liliana

PY - 2014/11/21

Y1 - 2014/11/21

N2 - The micronucleus test is a well-established DNA damage assay in human monitoring. The test was proposed as a promising marker of cancer risk/ susceptibility mainly on the basis of studies on breast cancer. Our recent metaanalysis showed that the association between micronuclei frequency, either at baseline or after irradiation, and breast cancer risk or susceptibility, has been evaluated in few studies of small size, with inconsistent results. The aim of the present study is to investigate the role of micronucleus assay in evaluating individual breast cancer susceptibility. Two-hundred and twenty untreated breast cancer patients and 295 female controls were enrolled in the study. All women were characterized for cancer family history and 155 subjects were evaluated for the presence of BRCA mutations. Micronuclei frequency was evaluated at baseline and after irradiation with 1-Gy gamma rays from a 137Cs source. The results show a non significant increase of frequency of micronucleated binucleated lymphocytes in cancer patients compared with the controls at baseline (Mean (S.E.): 16.8 (0.7) vs 15.7 (0.5), but not after irradiation (Mean (S.E.): 145.8 (3.0) vs 154.0 (2.6)). Neither a family history of breast cancer nor the presence of a pathogenic mutation in BRCA1/2 genes were associated with an increased micronuclei frequency. Our results do not support a significant role of micronucleus frequency as a biomarker of breast cancer risk/susceptibility.

AB - The micronucleus test is a well-established DNA damage assay in human monitoring. The test was proposed as a promising marker of cancer risk/ susceptibility mainly on the basis of studies on breast cancer. Our recent metaanalysis showed that the association between micronuclei frequency, either at baseline or after irradiation, and breast cancer risk or susceptibility, has been evaluated in few studies of small size, with inconsistent results. The aim of the present study is to investigate the role of micronucleus assay in evaluating individual breast cancer susceptibility. Two-hundred and twenty untreated breast cancer patients and 295 female controls were enrolled in the study. All women were characterized for cancer family history and 155 subjects were evaluated for the presence of BRCA mutations. Micronuclei frequency was evaluated at baseline and after irradiation with 1-Gy gamma rays from a 137Cs source. The results show a non significant increase of frequency of micronucleated binucleated lymphocytes in cancer patients compared with the controls at baseline (Mean (S.E.): 16.8 (0.7) vs 15.7 (0.5), but not after irradiation (Mean (S.E.): 145.8 (3.0) vs 154.0 (2.6)). Neither a family history of breast cancer nor the presence of a pathogenic mutation in BRCA1/2 genes were associated with an increased micronuclei frequency. Our results do not support a significant role of micronucleus frequency as a biomarker of breast cancer risk/susceptibility.

UR - http://www.scopus.com/inward/record.url?scp=84912099624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912099624&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0112354

DO - 10.1371/journal.pone.0112354

M3 - Article

C2 - 25415331

AN - SCOPUS:84912099624

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e112354

ER -